NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HD-23-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to form Transporter Elucidation Centers (TECs) as part of a Transporter Elucidation Network (TEN). TECs funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will address key knowledge gaps in functional transport of nutrients and drugs to the developing fetus and infant through a focus on human placenta, lactating mammary gland, and developing gut. Such projects may necessitate deorphanization and characterization of understudied transporters and functional variants. The NICHD-funded TECs will work together to generate knowledge and resources that will be shared with the broader research community to advance our understanding of nutrient, drug, and supplement transport to the developing fetus and infant.
Notice NOT-HD-22-042 from the NIH Guide for Grants and Contracts
Notice NOT-EY-22-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-22-020 from the NIH Guide for Grants and Contracts. The purpose of this fundng opportunity announcemnt (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
Notice NOT-AR-23-005 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-079 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) awardees from underrepresented groups (URGs), while promoting scientific advancements through diversification of NCIs investigator pool. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply.
Funding Opportunity PAR-22-233 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support research to understand health outcomes related to an unexpected and/or time-sensitive event (e.g., emergent environmental threat; pandemic; change in local, state, or national policy; natural disaster). Applications in response to this FOA must demonstrate that the research proposed is time-sensitive and must be initiated with minimum delay due to a limited window of opportunity to collect baseline data, answer key research questions, and/or prospectively evaluate a new policy or program. This FOA is intended to support opportunities in which empirical study could only be available through expedited review and funding, necessitating a substantially shorter process than the typical NIH grant review/award cycle. The time from submission to award is expected to occur within 4-5 months. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.
Funding Opportunity PAR-22-202 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
Funding Opportunity PAR-22-200 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Funding Opportunity RFA-AG-23-018 from the NIH Guide for Grants and Contracts. This RFA supports a national survey of professional dementia care providers and link consented survey respondents (providers and institutional representative) that consent to administrative data (e.g., electronic health records, claims, payroll, other institutional and state level data). This new resource anticipates the integration from administrative sources with the provider survey to expand research on the dementia care workforce, supply of skilled labor, and provide deeper insight into how professional care providers and institutions provide care for persons living with dementia. The national survey will oversample individuals from populations underrepresented in research on Alzheimers disease and related dementias (AD/ADRD) who serve in various professional caregiving roles (e.g., physicians, other care providers such as licensed practical nurses [LPNs], social workers) and institutions serving predominately underrepresented populations. This will allow examination of how the characteristics of professional care providers and the institutions employing them lead to variation in care provided to persons living with dementia and identify modifiable organization and individual behaviors that can improve overall health care delivery and eliminate AD/ADRD disparities.
Notice NOT-HL-22-048 from the NIH Guide for Grants and Contracts
Notice NOT-HG-22-033 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-22-245 from the NIH Guide for Grants and Contracts. This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.
Funding Opportunity RFA-ES-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for multi-component projects that will investigate the impact of climate change on emerging public health threats associated with marine and Great Lakes Basin environments. The focus of the program will be to support research on the exposures, toxicities and human health impacts that arise in these environments and how climate change is influencing these factors now and in the future. The FOA solicits applications that will achieve program goals through integrated, multidisciplinary scientific approaches and a community engagement component.
Notice NOT-GM-22-019 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-198 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-205 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-22-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for a Data Analysis Center for the NIH Environmental influences on Child Health Outcomes (ECHO) program. The Data Analysis Center's main roles are to 1) lead, standardize, and integrate ECHO Cohort Protocol data capture, management, and storage through a central data system; 2) provide analytic support and expertise to analysis proposals approved by the ECHO Cohort consortium; and 3) enrich research infrastructure and data science to facilitate broader sharing of ECHO Cohort data and resources with the scientific community. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for follow-up of existing ECHO Cohort participants and for recruitment of new pregnant participants (RFA XXXX), for Cohort Study Sites only for follow-up of existing ECHO Cohort participants (RFA XXXX), for Cohort Study Sites only for recruitment of new pregnant participants (SEE RFA XXXX), for an ECHO Coordinating Center (RFA XXXX), for an ECHO Measurement Core (RFA XXXX), and for an ECHO Laboratory Core (RFA XXXX).
Funding Opportunity RFA-OD-22-021 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite applications for a Coordinating Center for the Environmental influences on Child Health Outcomes (ECHO) program. The ECHO Cohort Coordinating Center will provide comprehensive operational leadership and an organizational infrastructure to manage and coordinate all ECHO Cohort activities. The Coordinating Centers main roles are to: 1) Provide oversight and effective project management for all aspects of the ECHO Cohort consortium; 2) Support multiple ECHO Cohort committees and serve as the centralized ECHO Cohort communications center; and 3) Administer the Opportunities and Innovation Fund. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for follow-up of existing ECHO Cohort participants and for recruitment of new pregnant participants (RFA XXXX), for Cohort Study Sites only for follow-up of existing ECHO Cohort participants (RFA XXXX), for Cohort Study Sites only for recruitment of new pregnant participants (RFA XXXX), for an ECHO Data Analysis Center (RFA XXXX), for an ECHO Measurement Core (RFA XXXX), and for an ECHO Laboratory Core (RFA XXXX).